U.S. FDA Gives Passing Grade To Ranbaxy Research Units
This article was originally published in The Pink Sheet Daily
Executive Summary
Even as Ranbaxy reels under the glare of FDA’s regulatory actions for GMP violations, its research units, which play an instrumental role in product filings for the United States, have come out unscathed. FDA officials are said to have recently cleared Ranbaxy’s research units after an inspection.